Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Fortunato Morabito, Sara Bringhen, Alessandra Larocca, Pierre Wijermans, Maria Victoria Mateos, Peter Gimsing, Carla Mazzone, Daniela Gottardi, Paola Omedè, Sonja Zweegman, Juan José Lahuerta, Renato Zambello, Pellegrino Musto, Valeria Magarotto, Martijn Schaafsma, Albert Oriol, Gunnar Juliusson, Chiara Cerrato, Lucio Catalano, Massimo GentileAna Isabel Turel, Anna Marina Liberati, Maide Cavalli, Davide Rossi, Roberto Passera, Stefano Rosso, Meral Beksac, Michele Cavo, Anders Waage, Jesus San Miguel, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo, Massimo Offidani

Research output: Contribution to journalArticle

Abstract

Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P

Original languageEnglish
Pages (from-to)355-362
Number of pages8
JournalAmerican Journal of Hematology
Volume89
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Melphalan
Thalidomide
Prednisone
Multiple Myeloma
Disease-Free Survival
Albumins
Bortezomib
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients : A retrospective case-matched study. / Morabito, Fortunato; Bringhen, Sara; Larocca, Alessandra; Wijermans, Pierre; Victoria Mateos, Maria; Gimsing, Peter; Mazzone, Carla; Gottardi, Daniela; Omedè, Paola; Zweegman, Sonja; José Lahuerta, Juan; Zambello, Renato; Musto, Pellegrino; Magarotto, Valeria; Schaafsma, Martijn; Oriol, Albert; Juliusson, Gunnar; Cerrato, Chiara; Catalano, Lucio; Gentile, Massimo; Isabel Turel, Ana; Marina Liberati, Anna; Cavalli, Maide; Rossi, Davide; Passera, Roberto; Rosso, Stefano; Beksac, Meral; Cavo, Michele; Waage, Anders; San Miguel, Jesus; Boccadoro, Mario; Sonneveld, Pieter; Palumbo, Antonio; Offidani, Massimo.

In: American Journal of Hematology, Vol. 89, No. 4, 2014, p. 355-362.

Research output: Contribution to journalArticle

Morabito, F, Bringhen, S, Larocca, A, Wijermans, P, Victoria Mateos, M, Gimsing, P, Mazzone, C, Gottardi, D, Omedè, P, Zweegman, S, José Lahuerta, J, Zambello, R, Musto, P, Magarotto, V, Schaafsma, M, Oriol, A, Juliusson, G, Cerrato, C, Catalano, L, Gentile, M, Isabel Turel, A, Marina Liberati, A, Cavalli, M, Rossi, D, Passera, R, Rosso, S, Beksac, M, Cavo, M, Waage, A, San Miguel, J, Boccadoro, M, Sonneveld, P, Palumbo, A & Offidani, M 2014, 'Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study', American Journal of Hematology, vol. 89, no. 4, pp. 355-362. https://doi.org/10.1002/ajh.23641
Morabito, Fortunato ; Bringhen, Sara ; Larocca, Alessandra ; Wijermans, Pierre ; Victoria Mateos, Maria ; Gimsing, Peter ; Mazzone, Carla ; Gottardi, Daniela ; Omedè, Paola ; Zweegman, Sonja ; José Lahuerta, Juan ; Zambello, Renato ; Musto, Pellegrino ; Magarotto, Valeria ; Schaafsma, Martijn ; Oriol, Albert ; Juliusson, Gunnar ; Cerrato, Chiara ; Catalano, Lucio ; Gentile, Massimo ; Isabel Turel, Ana ; Marina Liberati, Anna ; Cavalli, Maide ; Rossi, Davide ; Passera, Roberto ; Rosso, Stefano ; Beksac, Meral ; Cavo, Michele ; Waage, Anders ; San Miguel, Jesus ; Boccadoro, Mario ; Sonneveld, Pieter ; Palumbo, Antonio ; Offidani, Massimo. / Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients : A retrospective case-matched study. In: American Journal of Hematology. 2014 ; Vol. 89, No. 4. pp. 355-362.
@article{42e594ce90a846b49056a7809350a606,
title = "Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study",
abstract = "Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21{\%} in the VMP patients and 13{\%} in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95{\%} CI 0.52-0.82; P",
author = "Fortunato Morabito and Sara Bringhen and Alessandra Larocca and Pierre Wijermans and {Victoria Mateos}, Maria and Peter Gimsing and Carla Mazzone and Daniela Gottardi and Paola Omed{\`e} and Sonja Zweegman and {Jos{\'e} Lahuerta}, Juan and Renato Zambello and Pellegrino Musto and Valeria Magarotto and Martijn Schaafsma and Albert Oriol and Gunnar Juliusson and Chiara Cerrato and Lucio Catalano and Massimo Gentile and {Isabel Turel}, Ana and {Marina Liberati}, Anna and Maide Cavalli and Davide Rossi and Roberto Passera and Stefano Rosso and Meral Beksac and Michele Cavo and Anders Waage and {San Miguel}, Jesus and Mario Boccadoro and Pieter Sonneveld and Antonio Palumbo and Massimo Offidani",
year = "2014",
doi = "10.1002/ajh.23641",
language = "English",
volume = "89",
pages = "355--362",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients

T2 - A retrospective case-matched study

AU - Morabito, Fortunato

AU - Bringhen, Sara

AU - Larocca, Alessandra

AU - Wijermans, Pierre

AU - Victoria Mateos, Maria

AU - Gimsing, Peter

AU - Mazzone, Carla

AU - Gottardi, Daniela

AU - Omedè, Paola

AU - Zweegman, Sonja

AU - José Lahuerta, Juan

AU - Zambello, Renato

AU - Musto, Pellegrino

AU - Magarotto, Valeria

AU - Schaafsma, Martijn

AU - Oriol, Albert

AU - Juliusson, Gunnar

AU - Cerrato, Chiara

AU - Catalano, Lucio

AU - Gentile, Massimo

AU - Isabel Turel, Ana

AU - Marina Liberati, Anna

AU - Cavalli, Maide

AU - Rossi, Davide

AU - Passera, Roberto

AU - Rosso, Stefano

AU - Beksac, Meral

AU - Cavo, Michele

AU - Waage, Anders

AU - San Miguel, Jesus

AU - Boccadoro, Mario

AU - Sonneveld, Pieter

AU - Palumbo, Antonio

AU - Offidani, Massimo

PY - 2014

Y1 - 2014

N2 - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P

AB - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P

UR - http://www.scopus.com/inward/record.url?scp=84897388164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897388164&partnerID=8YFLogxK

U2 - 10.1002/ajh.23641

DO - 10.1002/ajh.23641

M3 - Article

C2 - 24273190

AN - SCOPUS:84897388164

VL - 89

SP - 355

EP - 362

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -